CKAP4 and cancer: Furthermore, an anti-CKAP4 polyclonal antibody (pAb) can significantly reduce xenograft tumor volume and weight caused by these cancer cell lines, suggesting that CAKP4 represents a novel molecular target for cancer therapy (Kimura et al., 2016; Kimura et al., 2019).